2012版血栓性血小板减少性紫癜诊断与治疗中国专家共识解读

详细信息

收稿日期: 2013-01-15

Received Date: 15 January 2013

[1]	张之南, 沈悌.血液病诊断及疗效标准[M].2版.北京:科学出版社, 1998:285-289.
[2]	中华医学会.临床诊疗指南血液学分册[M].北京:人民卫生出版社, 2006:107-108.
[3]	SADLER J E.Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J].Blood, 2008, 112:11-18.
[4]	SADLER J E, PONCZ M.Antibody-mediated thrombotic disorders:thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia[M]//KAUSHANSKY K, LICHTMAN M A, BEULTER E, et al.Williams Hematology.8th ed.The McGraw-Hill Companies.Inc, 2010:2163-2183.
[5]	苏健, 白霞, 刘芳, 等.血管性血友病因子裂解酶功能检测在血栓性血小板减少性紫癜诊断中的意义[J].中华检验医学杂志, 2006, 29(5):414-416.
[6]	KOKAME K, NOBE Y, KOKUBO Y, et al.FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay[J].Br J Haematol, 2005, 129:93-100.
[7]	BRESIN E, GASTOLDI S, DAINA E, et al.Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies[J].Thromb Haemost, 2009, 101:233-238.